P W Collins

List of Publications by Year
in descending order

159 papers	9,500 citations	34105 52 h-index	42399 92 g-index
163 all docs	163 docs citations	163 times ranked	4999 citing authors

#	Article	IF	Citations
1	Introduction of standardized, cumulative quantitative measurement of blood loss into routine maternity care. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 1491-1497.	1.5	6
2	The sensitivity and specificity of rotational thromboelastometry (ROTEM) to detect coagulopathy during moderate and severe postpartum haemorrhage: a prospective observational study. International Journal of Obstetric Anesthesia, 2022, 49, 103238.	0.4	20
3	Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study. Blood Advances, 2022, 6, 902-908.	5.2	15
4	Comparison of haematological indices and transfusion management in severe and massive postpartum haemorrhage: analysis of a two-year national prospective observational study. International Journal of Obstetric Anesthesia, 2022, 50, 103547.	0.4	6
5	The role of procoagulant phospholipids on the surface of circulating blood cells in thrombosis and haemostasis. Open Biology, 2022, 12, 210318.	3.6	12
6	The bleeding phenotype in people with nonsevere hemophilia. Blood Advances, 2022, 6, 4256-4265.	5.2	10
7	Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study. Blood, 2021, 137, 1818-1827.	1.4	43
8	Clinical phenotype of severe and moderate haemophilia: Who should receive prophylaxis and what is the target trough level?. Haemophilia, 2021, 27, 192-198.	2.1	19
9	Reduction in massive postpartum haemorrhage and red blood cell transfusion during a national quality improvement project, Obstetric Bleeding Strategy for Wales, OBS Cymru: an observational study. BMC Pregnancy and Childbirth, 2021, 21, 377.	2.4	29
10	Immune tolerance induction in severe haemophilia A: A UKHCDO inhibitor and paediatric working party consensus update. Haemophilia, 2021, 27, 932-937.	2.1	16
11	Utility of viscoelastography with TEG 6s to direct management of haemostasis during obstetric haemorrhage: a prospective observational study. International Journal of Obstetric Anesthesia, 2021, 47, 103192.	0.4	20
12	The incidence, aetiology, and coagulation management of massive postpartum haemorrhage: a two-year national prospective cohort study. International Journal of Obstetric Anesthesia, 2021, 47, 102983.	0.4	19
13	Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously treated individuals with haemophilia A or B. The Cochrane Library, 2021, 2021, CD014201.	2.8	5
14	The procoagulant activity of tissue factor expressed on fibroblasts is increased by tissue factor-negative extracellular vesicles. PLoS ONE, 2020, 15, e0240189.	2.5	5
15	A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients. Thrombosis and Haemostasis, 2020, 120, 747-757.	3.4	8
16	International recommendations on the diagnosis and treatment of acquired hemophilia A. Haematologica, 2020, 105, 1791-1801.	3.5	182
17	Incidence of postpartum haemorrhage defined by quantitative blood loss measurement: a national cohort. BMC Pregnancy and Childbirth, 2020, 20, 271.	2.4	34
18	Modeling to Predict Factor VIII Levels Associated with Zero Bleeds in Patients with Severe Hemophilia A Initiated on Tertiary Prophylaxis. Thrombosis and Haemostasis, 2020, 120, 728-736.	3.4	19

#	Article	IF	Citations
19	Designing and implementing an all Wales postpartum haemorrhage quality improvement project: OBS Cymru (the Obstetric Bleeding Strategy for Wales). BMJ Open Quality, 2020, 9, e000854.	1.1	14
20	Title is missing!. , 2020, 15, e0240189.		0
21	Title is missing!. , 2020, 15, e0240189.		0
22	Title is missing!. , 2020, 15, e0240189.		0
23	Title is missing!. , 2020, 15, e0240189.		0
24	Core outcome sets for prevention and treatment of postpartum haemorrhage: an international Delphi consensus study. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 83-93.	2.3	70
25	Management of postpartum haemorrhage: from research into practice, a narrative review of the literature and the Cardiff experience. International Journal of Obstetric Anesthesia, 2019, 37, 106-117.	0.4	62
26	Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review. Research and Practice in Thrombosis and Haemostasis, 2019, 3, 528-541.	2.3	18
27	Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A: Combined analysis of three studies. Haemophilia, 2019, 25, 398-407.	2.1	27
28	Phospholipid membranes drive abdominal aortic aneurysm development through stimulating coagulation factor activity. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 8038-8047.	7.1	22
29	Mycophenolate mofetil as adjunctive therapy in acquired haemophilia A. Haemophilia, 2019, 25, e59-e65.	2.1	8
30	Treatment regimens and outcomes in severe and moderate haemophilia A in the UK: The THUNDER study. Haemophilia, 2019, 25, 205-212.	2.1	51
31	Real life experiences of a <scp>PK</scp> dosing studyâ€"Challenges and lessons learned.. Haemophilia, 2018, 24, e145-e148.	2.1	2
32	Intracranial haemorrhage in children with inherited bleeding disorders in the <scp>UK</scp> 2003â€2015: A national cohort study. Haemophilia, 2018, 24, 641-647.	2.1	40
33	Retrospective Review of a Prothrombin Complex Concentrate (Beriplex P/N) for the Management of Perioperative Bleeding Unrelated to Oral Anticoagulation. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 1159-1169.	1.7	15
34	Setting the stage for individualized therapy in hemophilia: What role can pharmacokinetics play?. Blood Reviews, 2018, 32, 265-271.	5.7	41
35	Perioperative replacement therapy in haemophilia B: An appeal to â€œBâ€•more precise. Haemophilia, 2018, 24, 611-618.	2.1	7
36	Pharmacokinetics, safety and efficacy of a recombinant factor <scp>IX</scp> product, trenonacog alfa in previously treated haemophilia B patients. Haemophilia, 2018, 24, 104-112.	2.1	14

#	Article	IF	Citations
37	Platelet heterogeneity in activation-induced glycoprotein shedding: functional effects. Blood Advances, 2018, 2, 2320-2331.	5.2	45
38	Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery. Journal of Thrombosis and Haemostasis, 2018, 16, 2196-2207.	3.8	9
39	Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 535-548.	2.3	50
40	The use of viscoelastic haemostatic assays in the management of major bleeding. British Journal of Haematology, 2018, 182, 789-806.	2.5	160
41	Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia, 2018, 24, 344-347.	2.1	73
42	The immunogenicity of ReFacto <scp>AF</scp> (moroctocog alfa <scp>AF</scp>â€<scp>CC</scp>) in previously untreated patients with haemophilia A in the United Kingdom. Haemophilia, 2018, 24, 896-901.	2.1	11
43	Enzymatically oxidized phospholipids restore thrombin generation in coagulation factor deficiencies. JCI Insight, 2018, 3, .	5.0	36
44	DioxolaneA3-phosphatidylethanolamines are generated by human platelets and stimulate neutrophil integrin expression. Redox Biology, 2017, 11, 663-672.	9.0	16
45	Experience of immune tolerance in a carrier of severe haemophilia A with inhibitor development postâ€surgery. Haemophilia, 2017, 23, e234-e235.	2.1	5
46	Acquired hemophilia <scp>A</scp>: Updated review of evidence and treatment guidance. American Journal of Hematology, 2017, 92, 695-705.	4.1	267
47	Firstâ€line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties. Haemophilia, 2017, 23, 654-659.	2.1	25
48	Enzymatic lipid oxidation by eosinophils propagates coagulation, hemostasis, and thrombotic disease. Journal of Experimental Medicine, 2017, 214, 2121-2138.	8.5	78
49	Theoretical Modeling of Coagulation Management With Therapeutic Plasma or Prothrombin Complex Concentrate. Anesthesia and Analgesia, 2017, 125, 1471-1474.	2.2	12
50	Minimal dataset for postâ€registration surveillance of new drugs in hemophilia: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2017, 15, 1878-1881.	3.8	11
51	The haemtrack home therapy reporting system: Design, implementation, strengths and weaknesses: A report from UK Haemophilia Centre Doctors Organisation. Haemophilia, 2017, 23, 728-735.	2.1	20
52	Networks of enzymatically oxidized membrane lipids support calcium-dependent coagulation factor binding to maintain hemostasis. Science Signaling, 2017, 10, .	3.6	40
53	Estimating and interpreting the pharmacokinetic profiles of individual patients with hemophiliaÂA or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2017, 15, 2461-2465.	3.8	65
54	Viscoelastometry guided fresh frozen plasma infusion for postpartum haemorrhage: OBS2, an observational study. British Journal of Anaesthesia, 2017, 119, 422-434.	3.4	60

#	Article	IF	Citations
55	Viscoelastometric-guided early fibrinogen concentrate replacement during postpartum haemorrhage: OBS2, a double-blind randomized controlled trial. British Journal of Anaesthesia, 2017, 119, 411-421.	3.4	143
56	The use of enhanced halfâ€life coagulation factor concentrates in routine clinical practice: guidance from <scp>UKHCDO</scp>. Haemophilia, 2016, 22, 487-498.	2.1	97
57	Facilitating the implementation of pharmacokineticâ€guided dosing of prophylaxis in haemophilia care by discrete choice experiment. Haemophilia, 2016, 22, e1-e10.	2.1	26
58	Recombinant longâ€acting glyco<scp>PEG</scp>ylated factor <scp>IX</scp> (nonacog beta pegol) in haemophilia B: assessment of target joints in multinational phase 3 clinical trials. Haemophilia, 2016, 22, 507-513.	2.1	24
59	Nonacog beta pegol (N9-GP) in haemophilia B: A multinational phase III safety and efficacy extension trial (paradigmâ„¢4). Thrombosis Research, 2016, 141, 69-76.	1.7	52
60	Human Platelets Utilize Cycloxygenase-1 to Generate Dioxolane A3, a Neutrophil-activating Eicosanoid. Journal of Biological Chemistry, 2016, 291, 13448-13464.	3.4	15
61	When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2016, 14, 1105-1109.	3.8	54
62	Thrombomodulin enhances complement regulation through strong affinity interactions with factor H and C3b-Factor H complex. Thrombosis Research, 2016, 145, 84-92.	1.7	25
63	Combined Quantification of the Global Proteome, Phosphoproteome, and Proteolytic Cleavage to Characterize Altered Platelet Functions in the Human Scott Syndrome. Molecular and Cellular Proteomics, 2016, 15, 3154-3169.	3.8	52
64	Platelet count and transfusion requirements during moderate or severe postpartum haemorrhage. Anaesthesia, 2016, 71, 648-656.	3.8	28
65	Unclassified bleeding disorders: outcome of haemostatic challenges following tranexamic acid and/or desmopressin. Haemophilia, 2016, 22, 285-291.	2.1	30
66	The haematological features and transfusion management of women who required massive transfusion for major obstetric haemorrhage in the <scp>UK</scp>: a population based study. British Journal of Haematology, 2016, 172, 616-624.	2.5	61
67	Association of peak factor <scp>VIII</scp> levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokineticâ€guided prophylaxis. Haemophilia, 2016, 22, 514-520.	2.1	58
68	Management of coagulopathy associated with postpartum hemorrhage: guidance from the SSC of the ISTH. Journal of Thrombosis and Haemostasis, 2016, 14, 205-210.	3.8	103
69	Commentary on Reconstituting Fibrinogen Concentrate to Maintain Blinding in a Double-blind, Randomized Trial in an Emergency Setting. Journal of Emergency Medicine, 2016, 50, 104-107.e1.	0.7	10
70	Platelet Control of Fibrin Distribution and Microelasticity in Thrombus Formation Under Flow. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 692-699.	2.4	53
71	Modelling FVIII Levels for Prediction of Zero Spontaneous-Joint Bleeding in a Cohort of Severe Hemophilia a Subjects with Target Joints Initiated on Tertiary Prophylaxis. Blood, 2016, 128, 2576-2576.	1.4	3
72	Fibrinogen concentrate versus placebo for treatment of postpartum haemorrhage: study protocol for a randomised controlled trial. Trials, 2015, 16, 169.	1.6	31

#	Article	IF	Citations
73	Measurement of blood loss during postpartum haemorrhage. International Journal of Obstetric Anesthesia, 2015, 24, 8-14.	0.4	77
74	Haemostatic management of obstetric haemorrhage. Anaesthesia, 2015, 70, 78.	3.8	129
75	Role of enhanced halfâ€life factor <scp>VIII</scp> and <scp>IX</scp> in the treatment of haemophilia. British Journal of Haematology, 2015, 169, 768-776.	2.5	51
76	The incidence of factor <scp>VIII</scp> inhibitors in severe haemophilia A following a major switch from fullâ€length to Bâ€domainâ€deleted factor <scp>VIII</scp>: a prospective cohort comparison. Haemophilia, 2015, 21, 219-226.	2.1	41
77	Selective angiographic embolization for recurrent elbow and knee haemarthroses in haemophilia: a retrospective case series. Haemophilia, 2015, 21, e226-8.	2.1	8
78	Coordinated Membrane Ballooning and Procoagulant Spreading in Human Platelets. Circulation, 2015, 132, 1414-1424.	1.6	139
79	Theoretical modelling of fibrinogen supplementation with therapeutic plasma, cryoprecipitate, or fibrinogen concentrate. British Journal of Anaesthesia, 2014, 113, 585-595.	3.4	106
80	Joint health scores in a haemophilia A cohort from Pakistan with minimal or no access to factor <scp>VIII</scp> concentrate: correlation with thrombin generation and underlying mutation. Haemophilia, 2014, 20, 426-434.	2.1	16
81	Identification and quantification of aminophospholipid molecular species on the surface of apoptotic and activated cells. Nature Protocols, 2014, 9, 51-63.	12.0	16
82	Fibrin-based clot formation as an early and rapid biomarker for progression of postpartum hemorrhage: a prospective study. Blood, 2014, 124, 1727-1736.	1.4	196
83	Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial. Blood, 2014, 124, 3880-3886.	1.4	163
84	Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. Blood, 2014, 124, 3389-3397.	1.4	110
85	Diagnosis and treatment of factor <scp>VIII</scp> and <scp>IX</scp> inhibitors in congenital haemophilia: (4th edition). British Journal of Haematology, 2013, 160, 153-170.	2.5	192
86	Measurement of factorÂVIII pharmacokinetics in routine clinical practice. Journal of Thrombosis and Haemostasis, 2013, 11, 180-182.	3.8	49
87	Diagnosis and management of acquired coagulation inhibitors: a guideline from <scp>UKHCDO</scp>. British Journal of Haematology, 2013, 162, 758-773.	2.5	118
88	Human platelets generate phospholipid-esterified prostaglandins via cyclooxygenase-1 that are inhibited by low dose aspirin supplementation. Journal of Lipid Research, 2013, 54, 3085-3097.	4.2	44
89	Characterization of platelet aminophospholipid externalization reveals fatty acids as molecular determinants that regulate coagulation. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 5875-5880.	7.1	62
90	Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood, 2012, 119, 612-618.	1.4	181

#	Article	IF	Citations
91	Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Blood, 2012, 120, 47-55.	1.4	284
92	Haemostatic monitoring during postpartum haemorrhage and implications for management. British Journal of Anaesthesia, 2012, 109, 851-863.	3.4	171
93	Population pharmacokinetic modeling for dose setting of nonacog beta pegol (N9â€GP), a glycoPEGylated recombinant factor IX. Journal of Thrombosis and Haemostasis, 2012, 10, 2305-2312.	3.8	58
94	Therapeutic challenges in acquired factor VIII deficiency. Hematology American Society of Hematology Education Program, 2012, 2012, 369-374.	2.5	31
95	Personalized prophylaxis. Haemophilia, 2012, 18, 131-135.	2.1	80
96	Pharmacokinetic properties of <scp>IB</scp>1001, an investigational recombinant factor <scp>IX</scp>, in patients with haemophilia B: repeat pharmacokinetic evaluation and sialylation analysis. Haemophilia, 2012, 18, 881-887.	2.1	23
97	Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2). Journal of Thrombosis and Haemostasis, 2012, 10, 622-631.	3.8	395
98	National audit of the use of fibrinogen concentrate to correct hypofibrinogenaemia. Transfusion Medicine, 2012, 22, 350-355.	1.1	27
99	Human-Cl Rhfviii Effectively and Safely Prevents Bleeding Episodes in Previously Treated Adult Patients with Severe Haemophilia A. Blood, 2012, 120, 1132-1132.	1.4	0
100	Therapeutic challenges in acquired factor VIII deficiency. Hematology American Society of Hematology Education Program, 2012, 2012, 369-74.	2.5	20
101	Standard haemostatic tests following major obstetric haemorrhage. International Journal of Obstetric Anesthesia, 2011, 20, 135-141.	0.4	168
102	Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood, 2011, 117, 6367-6370.	1.4	173
103	Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia, 2011, 17, 2-10.	2.1	170
104	Management of acquired haemophilia A. Journal of Thrombosis and Haemostasis, 2011, 9, 226-235.	3.8	105
105	Pharmacokinetic Behavior of IB1001, An Investigational Recombinant Factor IX, in Patients with Hemophilia B: Repeat Pharmacokinetic Study and Subgroup Analysis. Blood, 2011, 118, 2267-2267.	1.4	0
106	Consensus recommendations for the diagnosis and treatment of acquired hemophilia A. BMC Research Notes, 2010, 3, 161.	1.4	149
107	Efficacy and safety of secondary prophylactic vs. onâ€demand sucroseâ€formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13â€month crossover study. Journal of Thrombosis and Haemostasis, 2010, 8, 83-89.	3.8	129
108	Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. Journal of Thrombosis and Haemostasis, 2010, 8, 269-275.	3.8	176

#	Article	IF	Citations
109	Comparative pharmacokinetics of plasmaâ€•and albuminâ€free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed ageâ€•related differences and implications for dose tailoring. Journal of Thrombosis and Haemostasis, 2010, 8, 730-736.	3.8	115
110	Predicting blood loss using novel thromboelastometry assays in cardiac surgery. Anaesthesia, 2010, 65, 99-100.	3.8	1
111	Blood transfusion and the anaesthetist: management of massive haemorrhage. Anaesthesia, 2010, 65, 1153-1161.	3.8	193
112	Advances in the understanding of acquired haemophilia A: implications for clinical practice. British Journal of Haematology, 2010, 148, 183-194.	2.5	94
113	A United Kingdom Haemophilia Centre Doctorsâ€™ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. British Journal of Haematology, 2010, 149, 498-507.	2.5	123
114	Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring. Journal of Thrombosis and Haemostasis, 2010, , no.	3.8	0
115	Phospholipid-esterified Eicosanoids Are Generated in Agonist-activated Human Platelets and Enhance Tissue Factor-dependent Thrombin Generation. Journal of Biological Chemistry, 2010, 285, 6891-6903.	3.4	115
116	The use of fibrinogen concentrate to correct hypofibrinogenaemia rapidly during obstetric haemorrhage. International Journal of Obstetric Anesthesia, 2010, 19, 218-223.	0.4	301
117	Acquired Haemophilia: Clinical and Demographic Data.Results of European Acquired Haemophilia Registry (EACH2).. Blood, 2010, 116, 1398-1398.	1.4	8
118	Use of a Population Pharmacokinetic Model of ADVATE In Pediatric and Adult Patients with Hemophilia A Permits Limited Blood Sampling for Individual Dose Tailoring.. Blood, 2010, 116, 1416-1416.	1.4	2
119	Inhibitor Eradication In Acquired Haemophilia A: Final Results of European Acquired Haemophilia Registry (EACH2). Blood, 2010, 116, 715-715.	1.4	7
120	Management of Bleeding In Acquired Hemophilia: Results of the European Acquired Hemophilia Registry (EACH2). Blood, 2010, 116, 716-716.	1.4	5
121	Acquired Haemophilia A and Pregnancy/Postpartum â€“ a Report From a European Registry. Blood, 2010, 116, 717-717.	1.4	5
122	Changing patterns of bleeding in patients with severe haemophilia A. Haemophilia, 2009, 15, 1210-1214.	2.1	109
123	Breakâ€through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. Journal of Thrombosis and Haemostasis, 2009, 7, 413-420.	3.8	295
124	Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort. Journal of Thrombosis and Haemostasis, 2009, 7, 787-794.	3.8	66
125	Population Pharmacokinetic Model of ADVATE in Pediatric and Adult Patients with Hemophilia A.. Blood, 2009, 114, 3492-3492.	1.4	1
126	Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome. Haemophilia, 2008, 14, 49-55.	2.1	49

#	Article	IF	Citations
127	Type 1 von Willebrand disease: application of emerging data to clinical practice. Haemophilia, 2008, 14, 685-696.	2.1	26
128	Thrombin generation during cardiac bypass surgery. Anaesthesia, 2008, 63, 1272-1272.	3.8	0
129	Rate of change of clot flexibility during cardiac bypass surgery. Anaesthesia, 2008, 63, 1273-1273.	3.8	0
130	Effect of Normal Variation in Factor VIII Pharmacokinetics on Prophylactic Dosing Requirements in Severe Classical Hemophilia.. Blood, 2008, 112, 1222-1222.	1.4	2
131	Rituximab for Treatment of Resistant Inhibitors in Severe Haemophilia a: A Consecutive National Cohort.. Blood, 2008, 112, 2275-2275.	1.4	0
132	Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood, 2007, 109, 1870-1877.	1.4	646
133	Treatment of acquired hemophilia A. Journal of Thrombosis and Haemostasis, 2007, 5, 893-900.	3.8	107
134	Inhibitors, what is the risk of treatment intensity?. Journal of Thrombosis and Haemostasis, 2007, 5, 1380-1382.	3.8	1
135	Global tests of haemostasis in critically ill patients with severe sepsis syndrome compared to controls. British Journal of Haematology, 2006, 135, 220-227.	2.5	144
136	Novel therapies for immune tolerance in haemophilia A. Haemophilia, 2006, 12, 94-101.	2.1	16
137	Risk factors for cardiovascular disease and hormone therapy in women. Heart, 2006, 92, iii24-iii28.	2.9	12
138	Clinical Implications of Pharmacokinetic Variables in the Management of Patients with Severe Hemophilia A.. Blood, 2006, 108, 1041-1041.	1.4	2
139	Plasma Microparticles Have Different Effects on Thrombin Generation in Platelet-Rich and Platelet-Poor Plasma.. Blood, 2006, 108, 1760-1760.	1.4	0
140	Prospective Analysis of Bruising in Children with and without an Inherited Bleeding Disorder.. Blood, 2006, 108, 1024-1024.	1.4	0
141	Global Haemostasis in Critically Ill Patients with Sepsis: Evidence for a Prothrombotic State.. Blood, 2005, 106, 2140-2140.	1.4	2
142	UKHCDO Acquired Haemophilia Study: A Complete National Cohort.. Blood, 2005, 106, 322-322.	1.4	1
143	Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albuminâ€free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A¹. Haemophilia, 2004, 10, 428-437.	2.1	143
144	A population based, unselected, consecutive cohort of patients with acquired haemophiliaÂA. British Journal of Haematology, 2004, 124, 86-90.	2.5	134

#	Article	IF	Citations
145	Pilot study of an Internet-based electronic patient treatment record and communication system for haemophilia, Advoy.com. Haemophilia, 2003, 9, 285-291.	2.1	31
146	Management of acquired haemophilia A - more questions than answers. Blood Coagulation and Fibrinolysis, 2003, 14, S23-S27.	1.0	23
147	Venous Thromboembolic Prophylaxis for Transurethral Prostatectomy: Practice among British Urologists. Journal of the Royal Society of Medicine, 2002, 95, 130-131.	2.0	6
148	High concentrations of coagulation factor VIII and thrombosis: is the factor VIII-binding domain of von Willebrand factor implicated?. British Journal of Haematology, 2001, 113, 655-657.	2.5	13
149	A new polymorphism in the human factor VIII gene: implications for linkage analysis in haemophilia A and for the evolution of int22h sequences. British Journal of Haematology, 2000, 111, 544-548.	2.5	5
150	Factor V Leiden and the common haemochromatosis mutation HFE C282Y: is there an association in familial venous thromboembolic disease?. British Journal of Haematology, 1999, 107, 210-212.	2.5	12
151	Specific analysis of the intron 22 Xba I polymorphism of the human factor VIII gene using long-distance PCR. British Journal of Haematology, 1999, 107, 566-568.	2.5	10
152	Increased bleeding associated with protease inhibitor therapy in HIV-positive patients with bleeding disorders. British Journal of Haematology, 1999, 107, 556-559.	2.5	38
153	Subependymal cells provide a faster response to ependymal injury than astrocytes in the hydrocephalic brain. Neuropathology and Applied Neurobiology, 1992, 18, 387-394.	3.2	9
154	Repair of the ependyma in hydrocephalic brains. Neuropathology and Applied Neurobiology, 1990, 16, 45-56.	3.2	17
155	Endotheliumâ€derived relaxing factor and nitroprusside compared in noradrenalineâ€and K+â€contracted rabbit and rat aortae.. Journal of Physiology, 1988, 400, 395-404.	2.9	32
156	Calcium retention and increased vascular reactivity caused by a hypothalamic sodium transport inhibitor. Clinical Science, 1988, 75, 197-202.	4.3	13
157	Alpha Adrenoceptor Blockade Improves Exercise Tolerance in Angina Pectoris. Clinical Science, 1984, 66, 40P-40P.	4.3	0
158	Endothelium-Dep Endent Calcium Fluxes in Rabbit Aorta. Clinical Science, 1984, 67, 28P-28P.	0.0	0
159	Failure of Thromboxane Synthetase Inhibition to Improve Exercise Capacity in Angina. Clinical Science, 1983, 65, 36P-36P.	4.3	0